 Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X,

Krix M, Bischof M et al (2003). Combined therapy with direct and indirect angiogenesis
inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res.
63:8890–8898.
 Adamcic U, Skowronski K, Peters C, Morrison J and Coomber BL (2012). The effect of
bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2
autocrine and intracrine signaling loops. Neoplasia. 14:612–623.
 Bergers G and Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev
Cancer;3:401 – 10
 Brambilla, Travis, WD, E, Noguchi, M, Nicholson, AG, Geisinger, K, Yatabe, Y and
Gazdar A (2012). Diagnosis of lung adenocarcinoma in resected specimens: implications
of the 2011 International Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society classification. Archives of Pathology and
Laboratory Medicine, 137(5), 685-705.
 Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J,
Dudley P, Broadbent N, Sproat G et al. (2011). Assessing the activity of cediranib, a
VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally
related PDGFR family. Mol Cancer Ther. 10:861–873.
 Cabebe E and Wakelee H (2007). Role of anti-angiogenesis agents in treating NSCLC:
Focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options
Oncol. 8:15–27.
 Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M, Jr et al. (2014).
A phase II, open-label study of ramucirumab in combination with paclitaxel and
carboplatin as first-line therapy in patients with Stage IIIB/IV non-small-cell lung
cancer. J Thorac Oncol. 
 Carlile A and Edwards C (1986). Poorly differentiated squamous carcinoma of the
bronchus: a light and electron microscopic study. J Clin Pathol 39:284–292
 Cooney MM, van Heeckeren W, Bhakta S, Ortiz J and Remick SC (2006). Drug insight:
vascular disrupting agents and angiogenesis—novel approaches for drug delivery. Nat
Clin Pract Oncol;3:682 – 92.
 Coultas L, Chawengsaksophak K and Rossant J (2005). Endothelial cells and VEGF in
vascular development. Nature;438:937 – 45.
 Demain, AL, Vaishnav and P (2011). Natural products for cancer
chemotherapy. Microbial biotechnology, 4(6), 687–699.
 Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R and Zeiher AM (1999).
Activation of nitric oxide synthase in endothelial cells by Akt-dependent
phosphorylation. Nature;399:601 – 5.
 Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S et al.(  2014 ). Phase 2,
randomized, open-label study of ramucirumab in combination with first-line pemetrexed
and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-
small cell lung cancer. Cancer.
 Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT
and Bremnes RM ( 2007). Inverse prognostic impact of angiogenic marker expression in
tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res. 13:6649–
6657.
 Erdurmus M, Yagci R, Yilmaz B et al. (2007). Inhibitory effects of topical
thymoquinone on corneal neovascularization. Cornea ;26:715 – 9.
 Ferrara N (2004). Vascular endothelial growth factor as a target for anticancer therapy.
Oncologist. 9(Suppl 1): 2–10.
 Gali-Muhtasib H, Diab-Assaf M, Boltze C et al.( 2004) Thymoquinone extracted from
black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-
dependent mechanism. Int J Oncol;25:857 – 66.
 Gali-Muhtasib HU, Abou Kheir WG, Kheir LA, Darwiche N and Crooks PA (2004).
Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in
neoplastic keratinocytes. Anticancer Drugs;15: 389 – 99.
 Gasparini G, Longo R, Toi M and Ferrara N (2005). Angiogenic inhibitors: a new
therapeutic strategy in oncology. Nat Clin Pract Oncol ;2:562 – 77.
 Hanahan D and Weinberg RA (2011). Hallmarks of cancer: The next generation. Cell.
144:646–674.
 Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS et al. ( 2010). Distinct
patterns of cytokine and angiogenic factor modulation and markers of benefit for
vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin
Oncol. ;28:193–201
 Hosseinzadeh H and Parvardeh S (2004). Anticonvulsant effects of thymoquinone, the
major constituent of Nigella sativa seeds, in mice. Phytomedicine;11:56 – 64.
 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J,
Baron A, Griffing S, Holmgren E, et al (2004). Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–
2342.
 Jain RK (2003). Molecular regulation of vessel maturation. Nat Med;9: 685 – 93.
 Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM et al.
(2004). Randomized phase II trial comparing bevacizumab plus carboplatin and
paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced
or metastatic non-small-cell lung cancer. J Clin Oncol. ;22:2184–91
 Kaseb AO, Chinnakannu K, Chen D et al. (2007). Androgen receptor and E2F-1 targeted
thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res;67:7782 – 8.
 Katiyar C, Gupta A, Kanjilal S and Katiar S (2012). Drug discovery from plant sources:
An integrated approach. Ayu, 33(1), 10–19.
 Kerr DJ (2004). Targeting angiogenesis in cancer: clinical development of bevacizumab.
Nat Clin Pract Oncol;1:39– 43.
 Kreisman H, Wolkove N and Quoix E (1992). Small cell lung cancer presenting as a
solitary pulmonary nodule. Chest;101:225–231.
 Lara PN, Jr., Twardowski P and Quinn DI (2004). Angiogenesis-targeted therapies in
prostate cancer. Clin Prostate Cancer 3:165 – 73.
 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro
A, Raoul JL, Forner A et al. (2008). SHARP Investigators Study Group. Sorafenib in
advanced hepatocellular carcinoma. N Engl J Med. 359:378–390.
 Manning BD and Cantley LC (2007). AKT/PKB signaling: navigating downstream.
Cell;129:1261 – 74.
 Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D
and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for
metastatic breast cancer. N Engl J Med. 357:2666–2676.
 Molhoek KR, Erdag G, Rasamny JK, Murphy C, Deacon D, Patterson JW, Slingluff CL
Jr and Brautigan DL (2011). VEGFR-2 expression in human melanoma: revised
assessment. Int J Cancer. 129:2807–2815.
 Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, Ryan A, Jürgensmeier JM
and Eckhardt SG (2009). Targeting vascular endothelial growth factor receptor-1 and -3
with cediranib (AZD2171): Effects on migration and invasion of gastrointestinal cancer
cell lines. Mol Cancer Ther. 8:2546–2558.
 Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C and Lee WM (2006).
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by
sorafenib (BAY43-9006). Am J Pathol;169:1875 – 85.
 Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D et al.( 2010).
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor
shrinkage in early-stage non-small cell lung cancer patients treated with
pazopanib. Cancer Res. ;70:2171–9
 Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J et al. (2009).
Phase II study of continuous daily sunitinib dosing in patients with previously treated
advanced non-small cell lung cancer. Br J Cancer. ;101:1543–8
 Patel, D, Shukla, S, Gupta and S (2007). Apigenin and cancer chemoprevention:
progress, potential and promise. International journal of oncology, 30(1), 233-245.
 Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J et al.( 2012).
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin
alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-
cell lung cancer. J Clin Oncol.  30:3084–92
 Presta, L., Chen, H, O’Connor, S, Chisholm, V, Meng, Y, Krummen, L et al. (1997)
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the
therapy of solid tumors and other disorders. Cancer Res 57: 4593–4599.
 Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U et al. (2011). A phase
II double-blind study to investigate efficacy and safety of two doses of the triple
angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung
cancer. Ann Oncol. ;22:1374–81
 Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J,
Czaykowski P, Dutcher J et al (2010). Phase III trial of bevacizumab plus interferon alfa
versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final
results of CALGB 90206. J Clin Oncol. 28:2137–2143.
 Roepke M, Diestel A, Bajbouj K et al. (2007). Lack of p53 augments thymoquinone-
induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol
Ther;6:160 – 9.
 Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M et al. (2010). Phase
III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell
lung cancer. J Clin Oncol. ;28:1835–42
 Selamat, SA, Galler, JS, Joshi, AD, Fyfe, MN, Campan, M., Siegmund, KD, Laird
Offringa and IA (2011). DNA methylation changes in atypical adenomatous hyperplasia,
adenocarcinom in situ, and lung adenocarcinoma. PloS one, 6(6), e21443.
 Shoieb AM, Elgayyar M, Dudrick PS, Bell JL and Tithof PK (2003). In vitro inhibition
of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J
Oncol;22:107 –.
 Smith, AH, Goycolea, M, Haque, R, Biggs and M L (1998). Marked increase in bladder
and lung cancer mortality in a region of Northern Chile due to arsenic in drinking
water. American journal of epidemiology, 147(7), 660-669.
 Socinski MA, Wang XF, Baggstrom MQ, Gu L, Stinchcombe TE, Edelman MJ et al.
( 2014). Sunitinib (S) switch maintenance in advanced non-small cell lung cancer
(NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III
trial. J Clin Oncol.  32:5s
 Somanath PR, Razorenova OV, Chen J and Byzova TV (2006). Akt1 in endothelial cell
and angiogenesis. Cell Cycle;5:512 – 8.
 Tomashefski, JJ, Connors, JA, Rosenthal, ES, Hsiue and IL (1990). Peripheral vs central
squamous cell carcinoma of the lung. A comparison of clinical features, histopathology,
and survival. Archives of pathology & laboratory medicine, 114(5), 468-474.
 Trang NT, Wanner MJ, Phuong le VN, Koomen GJ and Dung NX (1993).
Thymoquinone from Eupatorium ayapana. Planta Med;59:99.
 Travis WD, Brambilla E, Mu¨ller-Hermelink HK et al. (2004). Pathology and genetics:
tumours of the lung, pleura, thymus and heart. Lyon (France): IARC;.
 Travis WD, Brambilla E, Van Schil P et al. (2011). Paradigm shifts in lung cancer as
defined in the new IASLC/ ATS/ERS lung adenocarcinoma classification. Eur Respir
J;38:239–43.
 V Subhose, P Srinivas, and A Narayana (2005). “Basic principles of pharmaceutical
science in Ayurvěda,” Bulletin of the Indian Institute of History of Medicine, vol. 35, no.
2, pp. 83–92,
 Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman
A, Steinberg SM, Liewehr DJ et al .(2006). Antiangiogenic and antitumor effects of
bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin
Oncol. 24:769–777.
 Worthen DR, Ghosheh OA and Crooks PA (1998). The in vitro anti-tumor activity of
some crude and purified components of blackseed, Nigella sativa L. Anticancer
Res;18:1527 – 32.
 Youssoufian H, Hicklin DJ and Rowinsky EK (2007). Review: monoclonal antibodies to
the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer
Res. 13:5544s–48s
 Zappa, C, Mousa and SA (2016). Non-small cell lung cancer: current treatment and
future advances. Translational lung cancer research, 5(3), 288.